MOONLAKE IMMUNO (MLTX)
(Delayed Data from NSDQ)
$52.76 USD
-0.65 (-1.22%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $52.16 -0.60 (-1.14%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MLTX 52.76 -0.65(-1.22%)
Will MLTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLTX
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
MLTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MLTX
MoonLake Pharmaceuticals (MLTX) Target Price Raised by Goldman Sachs | MLTX Stock News
Beyond the Balance Sheet: What SWOT Reveals About MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics GAAP EPS of -$0.87 misses by $0.16
MoonLake (MLTX) Reports Strong Q2 with Key Program Progress
MoonLake Immunotherapeutics Reports Q2 2025 EPS of -$0. ...